I’m very excited to share that my PhD work is now published @eLife! We used a combination of genetics, cell biology and biochemistry to identify a new endosomal complex in yeast, which we named VINE 🌿 Early access here: https://t.co/BUF7s3xYjL. (1/n).
"Reliable protein-protein docking with AlphaFold, Rosetta and replica-exchange"
Some promising results on antibody-antigen complex prediction
https://t.co/vlUszvFCwB
"Here, we successfully use LIVE-PAINT to image yeast membrane proteins that do not tolerate the direct fusion of a fluorescent protein by using peptide tags as short as 5-residues"
https://t.co/GmbdPvD9lR
Finally the community has a reliable, specific and high affinity probe to detect PI(3,5)P2 ! I am very excited about the new insights that this new tool will deliver about how this rare phospholipid controls diverse cellular events. Been great working on this with @jasonkinglab
I’m excited to share that after five amazing years with @conibear_liz and @UBC@CMMT_UBC, I have defended my doctoral dissertation and finished my PhD in Medical Genetics.
We made some exciting discoveries over the years, and published papers that I’m truly proud of. 1/n.
@PerryHo21793268@uvic@UVicBCMB@Camosun@SuferDrude@pcstirling@HieterLab@UBC Most of all, I want to thank @conibear_liz for being such an inspiring mentor and fiercely creative scientific role model. It was a privilege to work in the Conibear lab, and it wouldn’t be possible to synthesize all of the things I learned from Liz into a single tweet. (3/n).
Arrowsmith Genetics is excited to be in Round 3 of the New Ventures BC competition. Looking forward to meeting our mentors and other NVBC ventures. #NVBC2023#BCtech#BCentrepreneurs
as a long time senior editor for @eLife I (MJF) thought I'd weigh in. When I first heard about the plan in its initial conception, I had my reservations for many of the same reasons some of you articulating. I've changed my mind. I think it is worth a shot
We have all (rightfully) complained about how flawed the current science publishing system is.
The @eLife team is now challenging this status quo by abandoning the traditional “accepted manuscript” title to instead publish everything that gets reviewed, along with an assessment.
Today, we’re introducing a new model that eliminates accept/reject decisions.
By publishing every paper with eLife reviews as a Reviewed Preprint, we plan to restore autonomy to authors, ensuring that they will be judged by what, not where, they publish. https://t.co/OAsiOVFStI
Manuscript accepted!! 🕺🏼🍾 This was a large, multi-lab project and I’m happy to have contributed to its success. Stay tuned for yeast membrane contact sites, lipid biology and a first glimpse at the (very) complicated inner workings of a potential new lipid transport protein—Lec1
Come work with us - exciting opportunity to get in at the early stage and substantially contribute to shaping the future and development of a new interdisciplinary and ambitious research program @UBCmedicine @UBC@UBCAging